Aspect Biosystems to Present on Liver and Pancreatic Tissue Therapeutics at American Society of Gene & Cell Therapy 25th Annual Meeting

May 09, 2022

Two posters and one oral presentation at ASGCT 2022 will highlight the development of Aspect’s bioengineered pancreatic and liver tissue therapeutics

Vancouver, BC, Canada - May 9, 2022 - Aspect Biosystems (“Aspect”), a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, will present on its liver and pancreas tissue therapeutic programs at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, held May 16-19, 2022 in Washington, DC and virtually. 

Aspect is leveraging its proprietary bioprinting technology, therapeutic cells, and materials science to create a pipeline of allogeneic cell-based tissue therapeutics that replace or repair damaged organ functions. These therapeutics are rationally engineered to be biologically functional, immune-protective, and suitable for surgical implantation to cure disease.  

“We look forward to sharing the encouraging preclinical data from both our liver and pancreatic tissue therapeutic programs at ASGCT,” said Tamer Mohamed, CEO at Aspect Biosystems. “These presentations represent the incredible progress our team is making and demonstrate the versatility of our platform technology in creating a new category of regenerative medicine that takes us beyond cell therapy towards bioengineered tissue therapeutics capable of addressing previously incurable diseases.” 

Presentation Details:

[Poster]: Functional Assessment of 3D Bioprinted Primary Human And Stem Cell-Derived Hepatocytes

  • Date/Time: Tuesday May 17, 2022, 5:30 PM - 6:30 PM
  • Session: Cell Therapies II
  • Poster Board Number: Tu-237

[Oral Presentation]: Bioprinting of Organotypic Aggregates of Hepatocytes and Mesenchymal Cells as a Platform for Liver Cell Therapy

  • Date/Time: Wednesday May 18, 2022, 4:45pm - 5:00pm
  • Presenter: Dr. Chris Dickman, Lead Research Scientist, Aspect Biosystems
  • Session: Engineered Cell Therapies
  • Location: Room 206

 [Poster]: A Novel Bioprinted Cell Therapy Platform Normalizes Blood Glucose Control in Diabetic Rats

  • Date/Time: Wednesday May 18, 2022, 5:30 PM - 6:30 PM
  • Session: Cell Therapy Product Engineering, Development or Manufacturing
  • Poster Board Number: W-304

All abstracts are available on the ASGCT website here

About Aspect Biosystems

Aspect Biosystems is a biotechnology company creating bioengineered tissue therapeutics to transform how we treat disease. Aspect is applying its microfluidic 3D bioprinting technology internally to develop these advanced therapeutics and partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at


Natalie Korenic
Aspect Biosystems

Back to all